skip to main content

Type 2 diabetes with albuminuric CKD — ABIM Board MCQ

Instant feedback + full explanation. One question, done properly.

ModerateEndocrinology/MetabolismType 2 diabetes with albuminuric CKDABIM Board

A 61-year-old with type 2 diabetes, coronary disease and CKD has eGFR 48 mL/min/1.73 m2 and UACR 520 mg/g despite maximally tolerated lisinopril. A1C is 7.8% on metformin. Which addition most directly lowers both kidney-progression and cardiovascular risk?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: EStart an SGLT2 inhibitor with proven kidney and cardiovascular benefit

The best answer is “Start an SGLT2 inhibitor with proven kidney and cardiovascular benefit”. Albuminuric diabetic CKD at this eGFR is a strong indication for an SGLT2 inhibitor, layered on renin-angiotensin inhibition. Its cardiorenal benefit is not dependent on needing a large A1C reduction. Glyburide creates prolonged hypoglycemia risk, short-acting nifedipine is not equivalent kidney protection, and delaying treatment sacrifices benefit.

Reference: KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease: https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf